Skip to content

Alto Neuroscience ANRO Operating Lease Liabilities

Operating Lease Liabilities at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.93M-18.7%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$39M-12.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$8.19M+19.8%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$10.61M+160%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$2.74M
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$4.67M

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,335%
Enterprise value$630.81M-940%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's operating lease liabilities?
Alto Neuroscience (ANRO) reported operating lease liabilities of $3.56M in Q1 2026.
How has Alto Neuroscience's operating lease liabilities changed year-over-year?
Alto Neuroscience's operating lease liabilities decreased by 19.4% year-over-year, from $4.41M to $3.56M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.